SLV-213 is under clinical development by Selva Therapeutics and currently in Phase I for Coronavirus Disease 2019 (COVID-19).
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback